Tyrosine hydroxylase polymorphism (C-824T) and hypertension: A population-based study

American Journal of Hypertension

Volumn 23, Issue 12, 2010, Pages 1306-1311

  Nielsen, Søren J ^a   Jeppesen, Jørgen ^a,b   Torp Pedersen, Christian ^b,c   Hansen, Tine W ^a   Linneberg, Allan ^a,b   Fenger, Mogens ^a,b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

ambulatory blood pressure; blood pressure; catecholamines; genetics; hypertension; sympathetic nervous system; tyrosine hydroxylase

Indexed keywords

CYTOSINE; THYMINE; TYROSINE 3 MONOOXYGENASE;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEART RATE; HUMAN; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; DENMARK; GENETICS; PROMOTER REGION;

ADULT; AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DENMARK; FEMALE; HUMANS; HYPERTENSION; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROMOTER REGIONS, GENETIC; TYROSINE 3-MONOOXYGENASE;

EID: 79952277440     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2010.165     Document Type: Article

References (17)

1. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009; 54:690-697.
2. Palatini P, Julius S. The role of cardiac autonomic function in hypertension and cardiovascular disease. Curr Hypertens Rep 2009; 11:199-205.
3. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983; 5:86-99.
4. Rao F, Zhang L, Wessel J, Zhang K, Wen G, Kennedy BP, Rana BK, Das M, Rodriguez-Flores JL, Smith DW, Cadman PE, Salem RM, Mahata SK, Schork NJ, Taupenot L, Ziegler MG, O'Connor DT. Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivo. Circulation 2007; 116:993-1006. (Pubitemid 47329564)
5. Sharma P, Hingorani A, Jia H, Ashby M, Hopper R, Clayton D, Brown MJ. Positive association of tyrosine hydroxylase microsatellite marker to essential hypertension. Hypertension 1998; 32:676-682. (Pubitemid 28480543)
6. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure and mortality: a population-based study. Hypertension 2005; 45:499-504. (Pubitemid 40411250)
7. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Home blood pressure measurements will not replace 24-hour ambulatory blood pressure monitoring. Hypertension 2009; 54:188-195.
8. Tunstall-Pedoe H, Kuulasmaa K, Men M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353:1547-1557. (Pubitemid 29219203)
9. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 2007; 49:2112-2119. (Pubitemid 46771048)
10. Kikuya M, Hansen TW, Thijs L, Bjklund-Bodegd K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 2007; 115:2145-2152. (Pubitemid 46659066)
11. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension 2003; 41:207-210. (Pubitemid 36204890)
12. Zhang K, Zhang L, Rao F, Brar B, Rodriguez-Flores JL, Taupenot L, O'Connor DT. Human tyrosine hydroxylase natural genetic variation: delineation of functional transcriptional control motifs disrupted in the proximal promoter. Circ Cardiovasc Genet 2010; 3:187-198.
13. Sarzani R, Dess Fulgheri P, Salvi F, Serenelli M, Spagnolo D, Cola G, Pupita M, Giantomassi L, Rappelli A. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 1999; 17: 1301-1305. (Pubitemid 29509509)
14. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, Manunta P, Marchitti S, Venturelli V, Bianchi G, Volpe M, Stella P. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 2006; 48:499-505. (Pubitemid 44093966)
15. Hasan KN, Shoji M, Sugimoto K, Tsutaya S, Matsuda E, Kudo R, Nakaji S, Suda T, Yasujima M. Association of novel promoter single nucleotide polymorphisms in vasopressin V1a receptor gene with essential hypertension in nonobese Japanese. J Hum Hypertens 2007; 21:825-827. (Pubitemid 47450011)
16. Pitzalis MV, Sarzani R, Dess Fulgheri P, Iacoviello M, Forleo C, Lucarelli K, Pietrucci F, Salvi F, Sorrentino S, Romito R, Guida P, Rappelli A, Rizzon P. Allelic variants of natriuretic peptide receptor genes are associated with family history of hypertension and cardiovascular phenotype. J Hypertens 2003; 21:1491-1496. (Pubitemid 36994127)
17. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009; 41: 348-353.